title: Can metronomic maintenance with weekly vinblastine prevent early relapse/progression after bevacizumab-irinotecan in children with low-grade glioma?
abstract: The association of bevacizumab and irinotecan has been shown to display a quick efficacy in low-grade glioma (LGG), but most patients relapse within months after cessation of therapy. From October 2012 to March 2014, four patients have been treated with irinotecan-bevacizumab followed by a metronomic maintenance with weekly vinblastine to try to prevent relapses. After a median follow-up of 23 months after the end of the bevacizumab-irinotecan induction, no patient relapsed. These observations suggest that maintenance chemotherapy with weekly vinblastine after an induction by irinotecan-bevacizumab can improve progression-free survival in children with LGG.
authors.affiliation: Service d'hématologie et Oncologie Pédiatrique, Centre Hospitalo-Universitaire Timone Enfants, AP-HM, Marseille, France.
authors.forename: Marie Amélie
authors.initials: MA
authors.lastname: Heng
authors.affiliation: Service de Radiothérapie, Centre Hospitalo-Universitaire Timone Enfants, AP-HM, Marseille, France.
authors.forename: Laetitia
authors.initials: L
authors.lastname: Padovani
authors.affiliation: Service de Radiologie, Centre Hospitalo-Universitaire Timone Enfants, AP-HM, Marseille, France.
authors.forename: Philippe
authors.initials: P
authors.lastname: Dory-Lautrec
authors.affiliation: Service d'hématologie et Oncologie Pédiatrique, Centre Hospitalo-Universitaire Timone Enfants, AP-HM, Marseille, France.
authors.forename: Jean Claude
authors.initials: JC
authors.lastname: Gentet
authors.affiliation: Service d'hématologie et Oncologie Pédiatrique, Centre Hospitalo-Universitaire Timone Enfants, AP-HM, Marseille, France.|Metronomics Global Health Initiative, Marseille, France.
authors.forename: Arnaud
authors.initials: A
authors.lastname: Verschuur
authors.affiliation: Metronomics Global Health Initiative, Marseille, France.|Aix-Marseille Université, INSERM, CRO2 UMR_S 911, Marseille, 13385, France.
authors.forename: Eddy
authors.initials: E
authors.lastname: Pasquier
authors.affiliation: Aix-Marseille Université, INSERM, CRO2 UMR_S 911, Marseille, 13385, France.|Service d'Anatomopathologie, Centre Hospitalo-Universitaire Timone Enfants, AP-HM, Marseille, France.
authors.forename: Dominique
authors.initials: D
authors.lastname: Figarella-Branger
authors.affiliation: Service Neurochirurgie Pédiatrique, Centre Hospitalo-Universitaire Timone Enfants, AP-HM, Marseille, France.
authors.forename: Didier
authors.initials: D
authors.lastname: Scavarda
authors.affiliation: Service d'hématologie et Oncologie Pédiatrique, Centre Hospitalo-Universitaire Timone Enfants, AP-HM, Marseille, France.|Metronomics Global Health Initiative, Marseille, France.|Aix-Marseille Université, INSERM, CRO2 UMR_S 911, Marseille, 13385, France.
authors.forename: Nicolas
authors.initials: N
authors.lastname: André
mesh_terms: D059250:Administration, Metronomic; D000293:Adolescent; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D000068258:Bevacizumab / Q000008:administration & dosage; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D002648:Child; D003131:Combined Modality Therapy; D018450:Disease Progression; D005260:Female; D005910:Glioma / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology*; D006801:Humans; D000077146:Irinotecan; D060046:Maintenance Chemotherapy; D008297:Male; D060787:Neoplasm Grading; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local; D019233:Retreatment; D012189:Retrospective Studies; D014747:Vinblastine / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D000068258:Bevacizumab; D014747:Vinblastine; D000077146:Irinotecan; D002166:Camptothecin
keywords: Angiogenesis; cancer; children; low-grade glioma; malignancies metronomic chemotherapy